Skip to content

Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery

Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01181492
Enrollment
176
Registered
2010-08-13
Start date
2008-11-30
Completion date
2010-04-30
Last updated
2013-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Surgery

Keywords

gene polymorphism, CYP3A4, fentanyl, HPLC, Analgesics

Brief summary

Purpose: This study aimed to investigate the impact of CYP3A4\*1G genetic polymorphism on metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Methods: 176 patients receiving elective lower abdominal surgery under general anesthesia were recruited into this study. Genotyping of CYP3A4\*1G was carried out by direct sequencing. The plasma fentanyl concentration was detected 30 min after anesthesia induction by high performance liquid chromatography-ultraviolet ray (HPLC-UV). The visual analog scale (VAS) was used for pain evaluation at rest during patient-controlled analgesia (PCA) treatment 0 h, 12 h and 24 h after operation. PCA fentanyl consumption and adverse effects were recorded during the first 24 h after surgery.

Interventions

None listed

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Aged 20-65 years * Anesthesiologists (ASA) physical status I or II; * With ±20% of ideal body weight; * Received PCA administration; * Agreed to participate the research

Exclusion criteria

* History of chronic pain; * Psychiatric diseases; * Diabetes mellitus; * Severe cardiovascular diseases; * Kidney or liver diseases; * Alcohol or drug abuse (according to the criteria of DSM-IV); * Pregnancy or at lactation period; * Consumed drugs (1week) or foods (3 days) known to inhibit or induce the expression of CYP3A4 enzymes prior to surgery; * Refused PCA administration; * Disagree to participate to the research

Design outcomes

Primary

MeasureTime frameDescription
CYP3A4*1G Polymorphism48 hours after operationAccording to CYP3A4\*1G polymorphism,patients are devided into three groups: \*1/\*1,\*1/\*1G,\*1G/\*1G

Secondary

MeasureTime frameDescription
The Visual Analog Scale 24 Hours Postoperative24 hours after operationThe visual analog scale (VAS) is used for pain evaluation at rest which from 0 to 10 (higher values represent morepain) during patient-controlled analgesia (PCA) treatment 24 h after operation
PCA Fentanyl Consumption24 h after surgeryPCA fentanyl consumption and adverse effects are recorded during the first 24 h after surgery.

Countries

China

Participant flow

Recruitment details

In Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, from November 2008 to April 2010 a total of 176 patients were recruited in this study precedure.

Participants by arm

ArmCount
*1/*1
Grouped by CYP3A4\*1G polymorphism, wild-type homozygote
103
*1/*1G
Grouped by CYP3A4\*1G polymorphism,\*1/\*1G: mutant heterozygote
66
*1G/*1G
Grouped by CYP3A4\*1G polymorphism,\*1G/\*1G: mutant homozygote
7
Total176

Baseline characteristics

Characteristic*1/*1G*1G/*1GTotal*1/*1
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
66 Participants7 Participants176 Participants103 Participants
Age Continuous47.1 years
STANDARD_DEVIATION 10.1
42.3 years
STANDARD_DEVIATION 7.8
45.9 years
STANDARD_DEVIATION 11.1
45.5 years
STANDARD_DEVIATION 11.7
Region of Enrollment
China
66 participants7 participants176 participants103 participants
Sex: Female, Male
Female
34 Participants4 Participants93 Participants55 Participants
Sex: Female, Male
Male
32 Participants3 Participants83 Participants48 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 1030 / 660 / 7
serious
Total, serious adverse events
0 / 1030 / 660 / 7

Outcome results

Primary

CYP3A4*1G Polymorphism

According to CYP3A4\*1G polymorphism,patients are devided into three groups: \*1/\*1,\*1/\*1G,\*1G/\*1G

Time frame: 48 hours after operation

Population: the number of participants for analysis was determined according to gene type of CYP3A4\*1G polymorphism which was carried by participant.

ArmMeasureValue (NUMBER)
*1/*1CYP3A4*1G Polymorphism103 participants
*1/*1GCYP3A4*1G Polymorphism66 participants
*1G/*1GCYP3A4*1G Polymorphism7 participants
Secondary

PCA Fentanyl Consumption

PCA fentanyl consumption and adverse effects are recorded during the first 24 h after surgery.

Time frame: 24 h after surgery

ArmMeasureValue (MEAN)Dispersion
*1/*1PCA Fentanyl Consumption395.0 μgStandard Deviation 138.5
*1/*1GPCA Fentanyl Consumption359.8 μgStandard Deviation 120.2
*1G/*1GPCA Fentanyl Consumption247.1 μgStandard Deviation 73.2
Secondary

The Visual Analog Scale 24 Hours Postoperative

The visual analog scale (VAS) is used for pain evaluation at rest which from 0 to 10 (higher values represent morepain) during patient-controlled analgesia (PCA) treatment 24 h after operation

Time frame: 24 hours after operation

ArmMeasureValue (MEAN)Dispersion
*1/*1The Visual Analog Scale 24 Hours Postoperative3.7 units on a scaleStandard Deviation 1.3
*1/*1GThe Visual Analog Scale 24 Hours Postoperative3.7 units on a scaleStandard Deviation 1.1
*1G/*1GThe Visual Analog Scale 24 Hours Postoperative3.4 units on a scaleStandard Deviation 1.3

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026